COMMUNIQUÉS West-GlobeNewswire

Daxor Corporation Announces $9 Million Registered Direct Offering
23/01/2026
OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase [...]
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
23/01/2026
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Aeroflow Health CEO Casey Hite Named to The Healthcare Technology Report’s Top Healthcare Technology CEOs of 2025 List
23/01/2026
Casey Hite is recognized for his strategic leadership in advancing healthcare technology to provide patients with better access to care ASHEVILLE, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering [...]
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
23/01/2026
PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and [...]
Adagene Provides Business Update and 2026 Objectives
23/01/2026
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated [...]
AMN Healthcare to Hold Fourth Quarter and Full Year 2025 Earnings Conference Call on Thursday, February 19, 2026
23/01/2026
DALLAS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its fourth quarter and full year 2025 financial results and first quarter 2026 outlook on [...]
Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
23/01/2026
FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and [...]
NextCure Provides Business Update
23/01/2026
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026 LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc [...]
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
23/01/2026
Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months [...]
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
23/01/2026
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Coloplast Finance B.V. - Decisions at the Annual General Meeting
23/01/2026
On 23 January 2026, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2024/25. In addition, EY [...]
Communiqué de presse : L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique
23/01/2026
L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères d'évaluation principaux et [...]
Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil
23/01/2026
Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccine Potential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S ( [...]
ONWARD Medical Appoints Ali Kiboro as Chief Financial Officer
23/01/2026
EINDHOVEN, the Netherlands, Jan. 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function [...]
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
23/01/2026
Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy [...]
Cheapest Compounded Semaglutide Without Insurance in 2026: What "Low-Cost" GLP-1 Pricing Often Excludes — SynergyRx Consumer Analysis
23/01/2026
A consumer pricing framework for "Cheapest Compounded Semaglutide," "Cheapest Compounded Semaglutide Online," and "Cheapest Compounded Semaglutide Pills" — focused on total monthly cost drivers, not endorsements New [...]
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
22/01/2026
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
22/01/2026
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults [...]
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
22/01/2026
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAH SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics [...]

Pages